Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
112 studies found for:    "Beta-thalassemia"
Show Display Options
Rank Status Study
21 Completed Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
Conditions: Beta-Thalassemia;   Thalassemia Major
Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO);   Drug: Deferiprone (DFP)
22 Recruiting Study of ACE-536 to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia
Condition: Beta-thalassemia.
Intervention: Drug: ACE-536
23 Recruiting Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Conditions: Iron Overload;   Beta-Thalassemia
Intervention: Drug: SP-420
24 Completed Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia
Condition: Beta Thalassemia
Interventions: Drug: HQK-1001;   Drug: Placebo
25 Completed Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition: Beta-Thalassemia
Interventions: Drug: ICL670;   Drug: deferoxamine
26 Completed Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
Condition: Beta Thalassemia Intermedia
Intervention: Drug: sodium 2,2 dimethylbutyrate
27 Completed Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
Conditions: Beta Thalassemia Major;   Congenital Anemias
Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
28 Withdrawn An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
Condition: β-thalassemia Major
Intervention: Drug: Deferasirox
29 Recruiting A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease
Conditions: Beta-Thalassemia Major;   Sickle Cell Disease
Intervention: Genetic: LentiGlobin BB305 Drug Product
30 Completed Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
Condition: Thalassemia Major
Intervention:
31 Completed Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Condition: Thalassemia Major
Intervention: Drug: Amlodipine
32 Unknown  Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
Conditions: Beta-Thalassemia;   Bone Marrow Transplantation
Interventions: Drug: Zoledronic acid;   Drug: Placebo
33 Unknown  Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
Conditions: Beta-thalassemia Major;   Iron Overload
Interventions: Drug: Silymarin (LEGALON);   Drug: Placebo
34 Completed Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions: Beta-thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention: Drug: Deferasirox
35 Completed Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
Condition: Beta-Thalassemia
Interventions: Drug: arginine butyrate;   Drug: epoetin alfa
36 Completed Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major
Condition: Thalassemia Major
Intervention:
37 Recruiting Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Conditions: Beta Thalassemia Major;   Beta Thalassemia Intermedia
Interventions: Drug: Dose level 1a;   Drug: Dose level 1b;   Drug: Dose level 2;   Drug: dose level 3;   Drug: dose level 4;   Drug: dose level 5
38 Active, not recruiting Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Condition: Thalassemia Major
Interventions: Biological: S-303 Treated Red Blood Cells (RBCs);   Biological: Conventional, untreated Red Blood Cells
39 Recruiting ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene
Condition: Confirmed Diagnosis of ß-thalassemia Major
Intervention: Genetic: Autologous CD34+ cells transduced with TNS9.3.55
40 Completed Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
Conditions: Osteoporosis;   Thalassemia Major;   Thalassemia Intermedia
Intervention: Drug: Neridronate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years